Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shows promise for blistering skin disease

NCT ID NCT04563923

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested avdoralimab, an antibody that blocks a specific immune signal, added to standard steroid cream for bullous pemphigoid—a severe blistering skin condition mostly affecting older adults. Fifteen participants received the combination to see if it leads to complete remission faster than steroids alone. The study is small and early, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Avdoralimab (a monoclonal antibody) plus clobetasol propionate cream
What this could lead to
If it works, this could point toward a more targeted treatment for bullous pemphigoid that reduces reliance on steroids alone.
What could go wrong
This is a very small, early-phase trial with only 15 participants, so results may not apply broadly. The drug may not prove more effective than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

15 people

The number who actually took part.

Started

Oct 2020

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * ≥ 18 years of age at the time of signing the informed consent document * Clinical diagnosis of BP confirmed by histology, immunohistochemistry and/or ELISA data * Patient requiring a treatment by superpotent topical steroids * Patients hospitalized for the treatment of their BP * For female, only post-menopaused patients * For male patients included in the study with partners of child bearing potential should agree to use highly effective contraception for the duration of the study and 6 months after the last dose of avdoralimab * Signed informed consent document prior to any study related assessments/procedures being conducted * Patient able to adhere to the study visit schedule and other protocol requirements * Patient registered to the French Social Security Exclusion Criteria: * Patients requiring systemic steroids according to the physician in charge * Contra indication to topical steroid * Use of systemic steroids or any immunosuppressive drugs in the past 4 weeks * Use of doxycycline or minocycline in the past 4 weeks * Use of systemic rituximab or omalizumab or dupilimumab in the past 12 weeks * Use of intravenous immunoglobulmins (IVIG) in the past 4 weeks * Impossibility to come every week to receive the injection * Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation * Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bullous pemphigoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bullous pemphigoid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bullous pemphigoid

Contacts and locations

Locations

  • APHM, Hôpital Nord

    Marseille, Bouches du rhône, 13000, France

  • APHM, Timone

    Marseille, Bouche Du Rhône, 13005, France

  • CHU Montpellier, Dermatologie

    Montpellier, Herault, 34005, France

  • CHU de Nice- Dermatologie

    Nice, Alpes-Maritimes, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.